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The role of the cerebellum in Alzheimer’s disease (AD) has been neglected for a long
time. Recent studies carried out using transgenic mouse models have demonstrated
that amyloid-β (Aβ) is deposited in the cerebellum and affects synaptic transmission and
plasticity, sometimes before plaque formation. A wide variability of motor phenotype has
been observed in the different murine models of AD, without a consistent correlation
with the extent of cerebellar histopathological changes or with cognitive deficits. The
loss of noradrenergic drive may contribute to the impairment of cerebellar synaptic
function and motor learning observed in these mice. Furthermore, cerebellar neurons,
particularly granule cells, have been used as in vitro model of Aβ-induced neuronal
damage. An unexpected conclusion is that the cerebellum, for a long time thought to
be somehow protected from AD pathology, is actually considered as a region vulnerable
to Aβ toxic damage, even at the early stage of the disease, with consequences on motor
performance.
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INTRODUCTION
Accumulating evidence indicates that Alzheimer’s disease (AD) is caused by the toxicity of
amyloid-β (Aβ) peptide (Haass and Selkoe, 2007; Shankar et al., 2008; Gouras et al., 2010).
Aβ peptides are generated from β-amyloid precursor protein (APP) via proteolytic cleavage
by the β- and γ-secretases; depending on the site of cleavage, different sized Aβ peptides
are generated, with Aβ1–40 and Aβ1–42 being the most toxic Aβ isoforms (Selkoe, 1998;
O’Brien and Wong, 2011). The soluble monomers can assemble into microaggregates, also
termed ‘‘soluble Aβ oligomers,’’ protofibrils and fibrils that accumulate in the brains of AD
subjects, forming insoluble amyloid plaques. It is now believed that soluble Aβ oligomers
are the critical pathogenic molecules in AD leading to synaptic and cognitive dysfunctions
(Selkoe, 2008; Ferreira et al., 2015). Accumulation of Aβ peptides and insoluble plaque
formation trigger a number of detrimental processes, including hyperphosphorylation of the
microtubule-associated protein tau, which leads to the formation of neurofibrillary tangles
and neuronal death (Kopeikina et al., 2012; Lasagna-Reeves et al., 2012). In accordance with
this hypothesis, recent evidence shows that, in transgenic mice expressing the human tau
protein, injection of Aβ1–42 monomers can induce tau hyperphosphorylation (Manassero
et al., 2016). However, the relevance of this mechanism in the cerebellum is not clear yet.
Frontiers in Aging Neuroscience | www.frontiersin.org 1 November 2018 | Volume 10 | Article 396
Hoxha et al. Cerebellum in Alzheimer’s Disease
Indeed, the cerebellum exhibits a lower expression of tau
compared to the cerebral cortex or to the hippocampus (Hu et al.,
2017).
Most of the research in the AD field has been focused on
characterizing the toxicity of Aβ on the medial temporal lobe
structures, especially the hippocampus, since their dysfunction
is considered the main cause of memory loss in AD, the earliest
cognitive deficit in this type of dementia (Hyman et al., 1984;
West et al., 1994; Scheff et al., 2007; Miniaci and De Leonibus,
2018). However, patients with AD can also develop language,
visual or motor symptoms, suggesting that Aβ pathology extends
beyond the hippocampus (Caine and Hodges, 2001; Lambon
Ralph et al., 2003; Albers et al., 2015).
Studies in both familial (FAD) and sporadic cases of AD
have demonstrated that the cerebellum is a vulnerable region
in AD patients (Schmahmann, 2016; Jacobs et al., 2018).
Elevated levels of Aβ oligomers have been observed in the
cerebellar cortex of AD patients (Larner, 1997; Sepulveda-
Falla et al., 2011). Furthermore, cases of early-onset FAD,
caused by mutation of presenilin-1 (PSEN1; the catalytic
subunits of γ-secretase), present Purkinje cell (PC) loss as
well as cerebellar deposition of Aβ and high levels of
hyperphosphorylated tau (Sepulveda-Falla et al., 2011, 2014).
Cerebellar atrophy is another characteristic feature of sporadic
AD which affects initially the portions of the cerebellar
regions connected to the default mode network, a set of
highly interacting brain regions (including angular gyrus,
middle temporal gyrus, precuneus and dorsal medial prefrontal
cortex) involved in cognition and extensively affected by
neurodegeneration such as in AD (Thomann et al., 2008;
Mevel et al., 2011; Guo et al., 2016). As the atrophy extends
to the cerebellar anterior lobe, patients may display motor
dysfunctions, i.e., impairments in gait and limb coordination
(Aggarwal et al., 2006).
In the last decades, mouse models of AD expressing mutant
human APP, sometimes together with mutant presenilins, have
been widely used for investigating the AD pathophysiology and
to establish new therapeutic strategies (Ashe and Zahs, 2010;
Puzzo et al., 2015; Drummond and Wisniewski, 2017; Sasaguri
et al., 2017). Most of the studies on these mouse models have
investigated the relationship between Aβ, memory impairment
and hippocampal synaptic plasticity, which is considered the
cellular correlate of learning and memory (Selkoe, 2002; Haass
and Selkoe, 2007; Shankar andWalsh, 2009). Less is known about
the effects of Aβ on cerebellar synaptic functions and motor
learning. Here, we provide for the first time a comprehensive
review of the literature regarding the cerebellar cellular and
molecular characterization in mouse models of AD, that can
help researchers to better understand cerebellar contribution in
neurodegenerative disorders and eventually provide the basis for
future research on this field.
CEREBELLAR MOTOR DYSFUNCTIONS IN
MOUSE MODEL OF AD
Motor deficits, initially classified as late-onset symptoms in AD
patients, have been considered for a long time as irrelevant
given the severe deterioration of cognitive functions (Ala and
Frey, 1995). However, there is increasing evidence that motor
performance is impaired even at the preclinical stage of the
disease (Pettersson et al., 2002; Buchman and Bennett, 2011) and
a link between motor skills deficits and AD onset probability has
also been proposed (Aggarwal et al., 2006).
Significant motor impairment has been also observed
in transgenic mice modeling AD (Table 1). For example,
APP23 transgenic mice overexpressing APP751 isoform
with the Swedish mutation (KM670/671NL) show motor
coordination deficit on the rotarod by 3 months of age, before
Aβ accumulation (Van Dam et al., 2003). Rotarod motor
coordination deficits preceding Aβ accumulation has been also
revealed in APP/PSEN1 mice, carrying APP695 isoform
with Swedish mutation and mutant presenilin 1 genes
(APPswe/PSEN1dE9; Kuwabara et al., 2014). Moreover,
APPswe/PSEN1dE9 mice show motor learning deficits on the
ErasmusLadder Task (Sepulveda-Falla et al., 2014). Interestingly,
in addition to motor coordination deficits on the beam test,
TgCRND8 mice, containing human APP695 with the Swedish
and Indiana (V717F) mutations, exhibit gait impairment on the
footprinting test (Russo et al., 2018).
On the other hand, several studies report motor deficits
only at later stages, when Aβ deposition is already present. For
example, 5xFAD mice, carrying human APP695 with Swedish,
Florida (APP I716V) and London (V717I) mutations plus
PSEN1 with M146L and L286V mutations, exhibit a severe
motor impairment at 11–13 months of age consisting of motor
coordination and motor learning deficits on the balance beam
test and accelerating rotarod, respectively (Ewers et al., 2006).
Moreover, 5xFAD transgenic mice show also changes in gait
parameters with a shorter stride length respect to wild type (WT)
mice on the footprinting test (O’Leary et al., 2018).
Nevertheless, there are other transgenic (Tg) lines that not
show motor dysfunctions even in the presence of cerebellar Aβ
accumulation, PC death and/or cerebellar electrophysiological
changes. These models include Tg2576 mice, which overexpress
a mutant form of APP695 with the Swedish mutation
(Dineley et al., 2002), and APP/PS1 mice overexpressing
APP695 Swedish mutant form plus PSEN1 with the L166P
mutation (APPswe/PSEN1-L166P; Hoxha et al., 2012).
These results, taken together, suggest that there is no clear
relationship between cerebellar Aβ deposits and motor deficits.
It is possible to hypothesize that soluble forms of Aβ, like
monomers or oligomers, are more directly related to motor
symptoms. This might explain the wide variability of the motor
phenotype observed in the different murine models of AD.
Motor deficits are also not correlated to the onset of cognitive
impairment. In fact, in TgCRND8 and APPswe/PSdeltaE9 mice,
motor deficits precede cognitive symptoms (Chishti et al., 2001;
Reiserer et al., 2007). In 5xFAD mice, the cognitive impairment
becomes apparent before motor deficits (Oakley et al., 2006). In
APP23 mice motor and cognitive symptoms start at the same age
(Van Dam et al., 2003).
Given these behavioral outcomes, it is possible that the
brain regions engaged in motor and cognitive performances are
differentially affected in AD animal models.
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TABLE 1 | Motor behavior and cerebellar electrophysiological phenotypes in murine models of Alzheimer’s disease (AD).
Mouse model Motor deficits Cerebellar electrophysiological
changes
References
APPswe/PSEN1-L166P
(Radde et al., 2006)
At pre-plaque stage:
• No motor coordination and motor
learning deficits on balance beam
test and accelerated rotarod test
• No gait impairment on footprinting
test
At pre-plaque stage:
• ↓ PC excitability
• unaffected PF-PC basal transmission
• unaffected CF-PC basal transmission
• ↓ CF-PC paired-pulse depression
• loss of large mIPSCs
Hoxha et al. (2012)
APPswe/PSEN1dE9
(Jankowsky et al., 2004)
At pre-plaque stage:
• Motor coordination deficits on
rotarod test
• Motor learning deficits on the
ErasmusLadder task
At pre-plaque stage:
• unaffected PF-PC basal transmission
• ↓ LTD at PF-PC synapse
Kuwabara et al. (2014)
At post-plaque stage:
• ↓ simple spike firing
• unaffected complex spike firing
Sepulveda-Falla et al. (2014)
TgCRND8
(Chishti et al., 2001)
At pre-plaque stage:
• Motor coordination deficits on
balance beam test
• Gait impairment on footprinting test
• No motor learning deficits on the
accelerated rotarod test
At pre-plaque stage:
• unaffected PF-PC basal transmission
• ↓ LTD at PF-PC synapse
• impaired noradrenergic modulation of
PF-PC synapse
Russo et al. (2018)
APP23
(Sturchler-Pierrat et al., 1997)
At pre-plaque stage:
• Motor coordination deficits on
rotarod test
n.d. Van Dam et al. (2003)
5×FAD
(Oakley et al., 2006)
At post-plaque stage:
• Motor coordination deficits on
balance beam test
• Motor learning deficits on the
accelerated rotarod test
• Gait impairment on footprinting test
n.d. Ewers et al. (2006)
and O’Leary et al. (2018)
Tg2576
(Hsiao et al., 1996)
At pre-plaque stage:
• No motor learning deficits on the
accelerated rotarod test
n.d. Dineley et al. (2002)
Abbreviations: n.d., not determined; PC, Purkinje cell; PF, parallel fiber; CF, climbing fiber; LTD, long term depression.
CEREBELLAR HISTOPATHOLOGICAL
CHANGES
Several studies in AD patients have reported diffuse amyloid
plaques in the cerebellum particularly in those with the pre-senile
onset of dementia (Larner, 1997). Aβ deposits were found in the
molecular layer of the cerebellar cortex extending to the PC layer,
and to a lower extent in the granule cell layer (Braak et al., 1989;
Sepulveda-Falla et al., 2011). The cerebellar histopathological
alterations appear earlier and are more severe in FAD compared
to the sporadic form of AD and are characterized by PC loss,
neuritic plaques and reactive astrocytosis (Fukutani et al., 1996).
Similar anatomical and temporal patterns of alterations
develop in the cerebellum of transgenic mice models of FAD.
For example, APPswe/PSEN1dE9 mice show few diffuse Aβ
deposits in the molecular layer at 6 months of age; the number
of cerebellar deposits increases with disease progression and at
higher rate in females vs. males (Lomoio et al., 2012; Kuwabara
et al., 2014). At 18/20 months of age, the Aβ plaques appear
surrounded by dystrophic neurites, microglia and astrocytes;
focal loss of PCs and degeneration of parallel fibers (PFs) have
been also observed. Significant loss of PCs (about 60%) has
been also revealed in Tg2576 mice (Kozuki et al., 2011); PC
loss progresses with animal aging and becomes much more
prominent in older transgenic mice. Deep cerebellar nuclei
(DCN) neurons appear vulnerable, even at the early stage of
disease, in 3xTg-AD mouse model that contains three mutant
genes, APPSwe, PS1M146V and tauP301L, leading to both plaque
and tangle pathology (Esquerda-Canals et al., 2013). In these
mice, loss of DCN is more pronounced at the level of the fastigial
nucleus than the interpositus and dentate nuclei.
Taken together these studies suggest that the involvement
of the cerebellum is quite variable depending on the mutation,
on the region and cell type analyzed. More experiments are
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needed to understand the role of specific mutations and the
involvement of tau in the pathology of animal models of AD.
A deeper level of understanding might be obtained by studies
of the alterations in cellular function by electrophysiological
techniques.
ALTERATION OF PC ACTIVITY AND
SYNAPTIC PLASTICITY IN MOUSE
MODELS OF AD
In the cerebellar cortex, elevated levels of soluble Aβ1–42
and Aβ oligomers are associated with the reduction of PC
intrinsic excitability. Patch-clamp recordings from PCs of
8-month-old APPswe/PSEN1-L166P mice revealed a larger
afterhyperpolarization following the first action potential and
longer second and third interspike intervals compared to
control PCs, which are indicative of higher frequency adaptation
(Table 1; Hoxha et al., 2012). No changes of PC membrane
excitability were found in 2-month-old APPswe/PSEN1-L166P
mice in which the Aβ levels are scarcely detectable. Since PCs are
the sole output of the cerebellar cortex, changes in their firing
properties can alter the activity of target neurons in the deep
cerebellar and vestibular nuclei (Hoxha et al., 2018).
According to different studies, Aβ1–42 does not affect the
PF-PC basal synaptic transmission (paired-pulse facilitation
and/or input-output relationship) whether it is autonomously
produced in AD mouse models, including APP/PS1, or
administered to cerebellar slices of WT mice, at a concentration
of 500 nM (Hoxha et al., 2012; Kuwabara et al., 2014; Russo
et al., 2018). Conversely, application of 1 µM Aβ1–42 peptides
determines a significant decrease in PF-PC synapse activity in
cerebellar slices of C57/Bl6mice (Arbez et al., 2007). Such effect is
associated with the decrease of miniature excitatory postsynaptic
currents (mEPSCs) amplitude and frequency suggesting an acute
effect of Aβ on both presynaptic and postsynaptic compartments.
According to the authors, the PF-PC synaptic alterations are
caused by the Aβ-induced activation of pro-apoptotic MAP
kinases JNK and p38 since their inhibition reversed the negative
effect of Aβ on mEPSC amplitude and frequency.
Single-unit extracellular recordings of PCs in vivo in the
cerebellar lobules (I–V) of 22-week old APPswe/PSEN1dE9 mice
revealed a firing frequency reduction of simple spikes, generated
by intrinsic membrane properties and PF inputs to PCs, whereas
the firing frequency of complex spikes, driven by climbing fiber
(CF) inputs, was not affected (Sepulveda-Falla et al., 2014).
The CF-PC basal synaptic transmission is also unaffected in
cerebellar slices of 8-month-old APPswe/PSEN1-L166P mice,
but the paired-pulse depression at the CF-PC synapse is reduced
suggesting an altered release of glutamate fromCFs (Hoxha et al.,
2012).
Interestingly, the PCs of APPswe/PSEN1-L166P mice also
showed a selective loss of large amplitude miniature inhibitory
postsynaptic currents mediated by gamma-aminobutyric acid
(GABA) receptors pointing to a reduction of the GABAergic
inhibitory drive on PCs (Hoxha et al., 2012). The decrease
of GABA inputs might be considered a compensatory
mechanism for the impairment of intrinsic excitability aimed at
re-establishing the physiological rate of PC firing. Alternatively,
the reduction in membrane excitability might be a homeostatic
compensation for the impairment of GABAergic transmission.
Dysfunction in the GABAergic signaling system has been also
documented in different brain regions of AD patients, including
the cerebellum (Mohanakrishnan et al., 1997; Seidl et al., 2001).
In particular, a significant loss of GABA content has been found
in post-mortem cerebellum samples from AD patients associated
with a significant decrease of glutamic acid decarboxylase
(GAD), the synthesizing enzyme of GABA (Burbaeva et al.,
2014). The results from animal models, together with the
immunohistochemical studies on human AD brains, indicate
that a GABAergic dysfunction is present in the AD cerebellum,
with possible consequences on the complex excitatory/inhibitory
balance, thus contributing to the disease pathophysiology
(McCormick, 1989).
Although basal synaptic transmission is intact at the PF-PC
synapse, cerebellar cortex synaptic plasticity deficits have been
observed in AD mice models in correlation with motor learning
impairment (Kuwabara et al., 2014). In most cases, the PF-
long-term depression (LTD) is impaired by either exogenous
synthetic Aβ1–42 application or by the abnormally high levels
of endogenous Aβ present in AD Tg mouse models. Russo
et al. (2018) have recently demonstrated that cerebellar synaptic
plasticity is affected early in the time course of the Alzheimer’s
pathology. Indeed, electrophysiological recordings on cerebellar
slices from 2-month-old TgCRND8 mice revealed a significant
alteration of LTD at the PF-PC synapse at the pre-plaque stage.
Indeed, TgCRND8 mice exhibit no Aβ plaques before 3-months,
but in several brain areas including the cerebellum small amounts
of Aβ peptides, which are likely to interfere with synaptic
plasticity and learning, have been detected (Chishti et al., 2001;
Yu et al., 2014).
These data suggest that, in the cerebellum, deficits of neuronal
signaling are present in early stages of AD, and they are
paralleled by the onset of motor symptoms. However, the results
are sparse and have been obtained in different animal models
of AD, so that currently it is difficult to draw conclusions.
Future studies are necessary to throw light on the cerebellar
neuronal dysfunctions that are involved in motor symptoms of
patients with AD. In addition, the activity of cerebellar neuronal
networks is under continuous control by diffuse-projection
neuromodulatory systems, some of which are severely affected
in AD. In the cerebellum, the noradrenergic system is one of the
most important neuromodulatory systems.
ALTERATION OF NORADRENERGIC
NEUROTRANSMISSION IN THE
CEREBELLAR CORTEX
Noradrenaline (NA) is a well-known neuromodulator involved
in a broad variety of brain processes, including attention,
arousal, decision making and memory. The cerebellar cortex
receives a widespread noradrenergic projection, from the locus
coeruleus (LC), which is consistent with the demonstration that
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the NA is involved in the modulation of cerebellar function
including motor learning (Pompeiano, 1998; Cartford et al.,
2004; Schweighofer et al., 2004).
Degeneration of LC and loss of noradrenergic innervation
in various brain regions have been revealed in AD in
correlation with decreased cognitive functions (Bondareff et al.,
1987; Bickford, 1993; Grudzien et al., 2007). Studies of
post-mortem tissue have demonstrated a significant reduction
of total LC cell number in MCI and AD as well as
decrease in norepinephrine transporter (NET), responsible
for the reuptake of NA, in several brain areas of AD
patients including the cerebellum (Tejani-Butt et al., 1993;
Gulyás et al., 2010; Kelly et al., 2017). Interestingly, AD
patients with aggressive behavior show higher levels of α2-
and β-adrenergic receptors (ARs) in the cerebellar cortex
compared to non-agitated AD subjects, whereas no significant
changes in ARs levels were found in prefrontal cortex and
hypothalamus (Russo-Neustadt and Cotman, 1997). According
to the authors, alterations of cerebellar ARs expression may
affect the PC activity and as a consequence, the cerebellar
output to the cerebral cortical areas encoding affective and
defensive/aggressive behavior.
Depletion of NA has also been reported in the cerebellum
of TgCRND8 mice starting at 4–5 weeks of age (Francis
et al., 2012). The loss of noradrenergic innervation is likely to
contribute to the impairment of cerebellar synaptic function
and eventually, motor learning observed in these mice (Russo
et al., 2018). Under normal conditions, activation of α-ARs
by NA or the α2-AR agonist UK 14,304, produces synaptic
depression at the PF-PC synapse whereas β2-AR activation
by isoproterenol facilitates the PF-PC synaptic transmission
(Lippiello et al., 2015; Hoxha et al., 2016). On the contrary,
application of α- or β-ARs agonist does not induce any
effect on PF-EPSCs in the cerebellar slices of 2-month-old
TgCRND8 (Figure 1). Furthermore, unlike controls, 2-month-
old TgCRND8 mice exhibit a significant impairment of
isoproterenol-induced plasticity at the PF-PC in correlation with
significant motor coordination and balance deficits (Russo et al.,
2018).
Further studies in APP23 transgenic mice have shown that
degeneration of LC results in elevated Aβ deposition and
increased neuroinflammation in brain areas usually innervated
by LC (Heneka et al., 2010). This result is in accordance
with the demonstration that NA positively modulates microglia
FIGURE 1 | Loss of noradrenergic modulation of the parallel fiber-Purkinje cell (PF-PC) synapse in TgCRND8 mice. In wild-type (WT) mice, the PF-PC excitatory
synaptic transmission is depressed by the endogenous agonist noradrenaline (NA) as well as by the α2-adrenergic receptor (AR) agonist UK 14,304, but it is
potentiated by the β-AR agonist isoproterenol. The same agonists do not induce any effect on PF-excitatory postsynaptic currents (EPSCs) in the cerebellar slices of
2-month-old TgCRND8. Bar graph shows the mean (±SEM) percentage of change of EPSC recorded in PCs of WT and TgCRND8 (Tg) mice. ∗∗p < 0.01 Tg vs. WT
(modified with permission from Russo et al., 2018).
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phagocytosis and migration, therefore facilitating Aβ clearance
and reducing the inflammatory response to Aβ.
MECHANISMS INVOLVED IN Aβ-INDUCED
NEUROTOXICITY
A general state of inflammation of the central nervous system has
been widely documented in AD (Hensley, 2010; Maione et al.,
2018). Amongst the elements contributing to the development
of neuroinflammation in AD, there are certain cell types,
such as astroglia and microglia, that manifest high reactivity
and morphological alterations (Akiyama et al., 2000). At the
cerebellar level, a severe astrocytosis has been found in the
granule layer and white matter of FAD patients, in absence of
amyloid plaques (Fukutani et al., 1996). Astrocytosis has been
also observed in sporadic AD patients, although the number of
astrocytes was significantly lower than in FAD patients.
Further studies in rats have demonstrated that cerebellar
astrocytosis can be directly induced by intracerebroventricular
administration of Aβ peptides. In particular, Aβ injection
determines a significant increase in astrocyte number in
the granular and molecular layers (Lee et al., 2014). In
addition, Aβ can also activate phagocytosis by microglia in
rat mixed granular/glial cell cultures causing the loss of
cerebellar neurons (Neniskyte et al., 2011). In the presence
of the inhibitor of microglial phagocytosis, L-leucine-methyl-
ester, the administration of Aβ1–42 (250 nM) does not induce
any granule cell loss. However, L-leucine-methyl-ester is not
able to prevent granule cell loss at higher concentrations
of Aβ1–42 (10 µM). This suggests that the loss of neurons
induced by low concentrations of Aβ is directly linked
to microglial activity, whereas in the presence of higher
concentrations of Aβ1–42 the cellular loss occurs through a
microglia-independent mechanism. According to Neniskyte
et al. (2011), the administration of Aβ1–42 induces the exposure
of phosphatidylserine (PS) on the neuronal surface and activates
phagocytosis by microglia. Indeed, in addition to the treatment
with phagocytosis inhibitors, antibodies to PS prevented Aβ1–42-
induced neuronal loss.
Interestingly, an increased secretion of β-amyloid has been
assessed in cerebellar granule cells undergoing apoptosis. Aβ can
activate signaling cascades responsible for the neurodegeneration
of nearby cells; the granular cellular death rate is reduced by anti-
Aβ antibodies (Galli et al., 1998).
The apoptotic effect of Aβ25–35 on cerebellar granule cells
involves the activation of different classes of caspase, including
caspase-2, -3 and -6 (Allen et al., 1999). These caspases can
cleave tau proteins to generate fragments with toxic activity, such
as NH2-26–44 tau fragment, which may impair the oxidative
phosphorylation leading to the accumulation of reactive oxygen
species (ROS; Atlante et al., 2008). The excessive presence of
free radicals and ROS in the nucleus determines the oxidation
of nucleic acids and, consequently, harmful mutations and
cellular death. An increase in 8-OH-adenine, 8-OH-guanosine
and fapyadenine in nuclear DNA has been reported in the
cerebellar cortex of patients in the last stage of AD (Wang
et al., 2005). The oxidative stress is associated with an increase
of redox-active iron at the early preclinical stage of AD. The
redox metal accumulation affects PCs less than other cerebellar
cell types, including glial cells, likely due to the different redox
environment within the cerebellum (Smith et al., 2010).
In TgCRND8 mice, accumulation of Aβ is accompanied
by an increase of oxidative stress (Yu et al., 2014). The same
mice show an increased cerebellar NADPH oxidase activation
at pre-plaque stage accompanied by enhanced phospholipid
peroxidation compared toWTmice (Russo et al., 2018). It should
be pointed out that the oxidative stress level in the cerebellum
is lower than in the cortex and this may be correlated with the
differences in the antioxidant activity and levels of trace metals
including iron.
CONCLUSIONS
In this review article, by exploiting the knowledge derived from
single and original studies, the involvement and contribution of
the cerebellum in AD are outlined for the first time. According
to these studies, the cerebellar involvement by AD pathology
is more pronounced than previously thought. Aβ cerebellar
deposits increase with disease progression in the cerebellar cortex
of both patients and mouse models of AD, leading to plaque
formation and loss of PCs. Further investigation on Tg mice
has recently provided important insight into the effects of Aβ
on cerebellar synaptic transmission and plasticity at the early
stage of disease, that may lead to motor coordination and
learning deficit. Such synaptic and motor learning alterations
are in part mediated by deficits in NA signaling. The in vitro
approach has also uncovered the role of cerebellar astrocytes
and microglia phagocytosis as well as oxidative stress in the Aβ-
induced neuronal damage.
Given the role of the cerebellum in motor and cognitive
processes, additional studies must be undertaken to understand
how neurodegenerative changes that develop progressively in
this brain structure impact the progression of AD from the
earliest to the final stages of the disease.
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